T2: A Couples-based Intervention for Transgender Women and Their Partners

Sponsor
University of Michigan (Other)
Overall Status
Recruiting
CT.gov ID
NCT04067661
Collaborator
University of California, San Francisco (Other), Brown University (Other)
240
1
2
41.9
5.7

Study Details

Study Description

Brief Summary

This project seeks to test the efficacy of a couples-based HIV prevention program in large-scale randomized controlled trial (RCT) to reduce HIV risk among transgender woman and their partners. This project involves enrolling a racially diverse sample of transgender women and their partners and randomizing 100 couples to either the couples-based HIV prevention intervention or an enhanced standard of care (SOC) control condition. Couples will be followed quarterly over 12-months. Analysis of study outcomes will utilize both individual- and dyadic-level data. The primary outcome is a composite measure of risk for HIV transmission which encompasses validated behavioral indicators of HIV risk as well as biomedical confirmation of viral suppression and PrEP adherence.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CHIP
  • Behavioral: Control
N/A

Detailed Description

Transgender women (trans women; individuals with a feminine and/or female gender identity who were assigned male at birth) are disproportionately affected by HIV. One of the most consistently reported contexts for HIV transmission among trans women is within a primary partnership. In this partnership context, trans women report low condom use, difficulty disclosing their HIV status and negotiating HIV prevention strategies, poor communication about whether they permit sex outside of the relationship, and low rates of routine HIV testing. Likewise, research among males who have sex with trans women has found high HIV prevalence, inconsistent condom use with trans women, and low engagement with HIV prevention services.5

For the past 10 years the investigators have conducted research to identify intervention targets for reducing HIV transmission in trans women and their partner using qualitative, survey, and intervention adaptation methodologies. Based on these conceptual and empirical understandings of HIV transmission in these dyads, the investigative team developed and pilot tested the first known couples-based HIV prevention program for trans women and primary partners (called "Couples HIV Intervention Program" or CHIP). CHIP was feasible, acceptable, and produced significant reductions in condomless sex acts with primary and casual partners and in number of casual partners at 3-month follow-up compared to a control group.

The project seeks to test the efficacy of the CHIP intervention on reductions in a Composite Risk for HIV (CR-HIV) outcome. CR-HIV is a binary indicator of couple HIV risk using validated measures of sexual behavior (defined as condomless anal or vaginal sex with a serodiscordant or unknown HIV status primary or outside partner), as well as PrEP use among HIV-negative participants and viral suppression among HIV-positive partners. The study involves two-arm prospective RCT in which 100 trans women and their partners (200 participants) will complete a Baseline assessment and then complete assessments every 3 months for 12 months. Recruitment and study activities will occur in San Francisco, California.

The primary specific aim is to:
  1. Evaluate the efficacy of CHIP on CR-HIV compared to an enhanced standard of care control condition. Hypothesis: It is hypothesize that couples in the CHIP condition will have lower CR-HIV at 12-month follow-up compared to couples in the control.
The secondary aims are to:
  1. Assess the effect of CHIP on theory-based mediators (i.e., communication, joint problem-solving).

  2. Explore partner gender (trans woman vs. male partner and couple HIV status (seroconcordant negative vs. serodiscordant) as potential moderators of the effect of CHIP on CR-HIV.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study involved a randomized controlled trial comparing the couples-based HIV prevention to an enhanced standard of care control conditionThe study involved a randomized controlled trial comparing the couples-based HIV prevention to an enhanced standard of care control condition
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Couples-Based Approach to HIV Prevention for Transgender Women and Their Male Partners
Actual Study Start Date :
Nov 1, 2019
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
Apr 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

Participants and their partners will complete four couples counseling sessions focused on developing and enhancing relationship skills to decrease HIV risk behaviors.

Behavioral: CHIP
The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
Other Names:
  • It Takes Two
  • Active Comparator: Control

    Participants and their partners will receive information and referrals on HIV risk and prevention strategies.

    Behavioral: Control
    Enhanced standard of care, which includes information and referrals on HIV risk and prevention.

    Outcome Measures

    Primary Outcome Measures

    1. Composite Risk for HIV [Changes in CR-HIV at 12-month follow-up]

      CR-HIV is a couple-level binary indicator of any HIV risk (e.g., yes=1 vs. no=0), which is an algorithm based on whether one or both partners report condomless anal or vaginal sex with a HIV serodiscordant or status-unknown primary or other partner in the past 3 months. If one or both partners in the dyad report condomless sex with a serodiscordant or status-unknown primary or other partner, then the couple is coded as 1 if (i) the HIV-negative participant is not adherent to PrEP and/or (ii) the HIV-positive participant is not virally suppressed.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age 18 or older

    • Self-report that they are in emotional and/or sexual relationship for at least three months

    • One partner must identify as a trans women (assigned the male gender at birth but identify as female or as a trans woman)

    • Both partners must have engaged in condomless sex within the past 6 months with any partner

    • Able to provide informed consent

    • Speak and read English

    Exclusion Criteria:
    • Currently psychotic, suicidal, or manic

    • Either partner reports that participating in the study would cause them physical harm

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of California, San Francisco San Francisco California United States 94158

    Sponsors and Collaborators

    • University of Michigan
    • University of California, San Francisco
    • Brown University

    Investigators

    • Study Director: Ellen Stein, University of California, San Francisco

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kristi Gamarel, Assistant Professor, University of Michigan
    ClinicalTrials.gov Identifier:
    NCT04067661
    Other Study ID Numbers:
    • F050837
    First Posted:
    Aug 26, 2019
    Last Update Posted:
    Mar 2, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kristi Gamarel, Assistant Professor, University of Michigan
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 2, 2022